Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
The guidelines are the result of a consensus of an international task force of MG experts.
Treatment has been linked to durable, symptom-free, treatment-free remission in several cases of MG.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Hypothalamus May Play a Central Role in Chronic Migraine
- An Interdisciplinary Approach to Advanced Parkinson's Care
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- Alzheimer's Mortality Increasing, But So Is At-Home Care
- Special Diets, Supplements for Autism Not Backed by Solid Evidence
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia